Oncolytics announces early preclinical data for pelareorep with RAS inhibitors

Filed June 1, 2026 · Period ending June 1, 2026 · ~1 min read

Key Changes

• medium

  Company released initial preclinical results showing pelareorep combined with RAS inhibitor therapies, targeting RAS-driven cancers. Plans additional studies with multiple RAS-targeted agents.

  Item 8.01 verify on EDGAR →
• medium

  Data represents early-stage research that could shape future clinical development strategy for the company's lead drug candidate in oncology.

  Press Release verify on EDGAR →